An Evolution in Public Health: The FDA’s Ongoing Recognition of Tobacco Harm Reduction
At this year’s Food and Drug Law Institute (FDLI) Tobacco and Nicotine Conference, Acting Director for the U.S. Food and Drug Administration’s Center for Tobacco Products (CTP), Dr. Bret Koplow, delivered a defining keynote — not marking a first, but rather a culmination of the FDA’s evolving stance on tobacco harm reduction (THR). The address…